Business

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

Click here to register Company plans to file its Earnings Report on November 14, 2025 on Form 10-Q for the quarter ended September 30, 2025 SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 /Jaguar Health, Inc. (NASDAQ:JAGX) today announced ...

articleJaguar Health, Inc.November 14, 20253/company/jaguar-animal-health-inc/news/jaguar-health-hold-investor-webcast-140000131
Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

About this update from Jaguar Health, Inc.

[{"type":"text","content":"Click here to register","length":22,"tagName":"p"},{"type":"text","content":"Company plans to file its Earnings Report on November 14, 2025 on Form 10-Q for the quarter ended September 30, 2025","length":116,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / November 14, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, November 17, 2025, at 8:30 a.m. Eastern to review third-quarter 2025 financials and provide corporate updates.","length":279,"tagName":"p"},{"type":"text","content":"Participation Instructions for Jaguar Investor Webcast","length":54,"tagName":"p","attribs":{}},{"type":"text","content":"When: Monday, November 17, 2025 at 8:30 AM Eastern Time","length":55,"tagName":"p","attribs":{}},{"type":"text","content":"Participant Registration & Access Link: Click Here","length":54,"tagName":"p","attribs":{}},{"type":"text","content":"About the Jaguar Health Family of CompaniesJaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.","length":1373,"tagName":"p"},{"type":"text","...

More updates from Jaguar Health, Inc.

Jaguarprescription medicinespharmaceuticals companyJaguar HealthMagdalena Biosciences